Evidence map›Paper›PMID 26729423›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2016

A G-protein Subunit-α11 Loss-of-Function Mutation, Thr54Met, Causes Familial Hypocalciuric Hypercalcemia Type 2 (FHH2).

Caroline M Gorvin, Treena Cranston, Fadil M Hannan, Nigel Rust, Asjid Qureshi, M Andrew Nesbit, Rajesh V Thakker

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Heritable hyperparathyroidism: Genetic insights and clinical implications.Best practice & research. Clinical endocrinology & metabolism · 2025
    Review
  3. Article
  4. Characterisation of aEndocrine oncology (Bristol, England) · 2025
    Article
  5. Familial states of primary hyperparathyroidism: an update.Journal of endocrinological investigation · 2024
    Review
  6. Review
  7. Article
  8. GNA11 Variants Identified in Patients with Hypercalcemia or Hypocalcemia.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023
    Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Misleading localization byBMC endocrine disorders · 2021
    Article
  15. Familial Hyperparathyroidism.Frontiers in endocrinology · 2021
    Review
  16. Clinical and Molecular Genetics of Primary Hyperparathyroidism.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2020
    Review
  17. Review
  18. Article
  19. Article
  20. Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Caroline M GorvinAcademic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Treena CranstonOxford Molecular Genetics Laboratory, Churchill Hospital, Oxford, UK.
Fadil M HannanAcademic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Nigel RustSir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Asjid QureshiDepartment of Diabetes and Endocrinology, Northwest London NHS Trust, London, UK.
M Andrew NesbitAcademic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Rajesh V ThakkerAcademic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
University of Oxford · GBChurchill Hospital · GBDiabetes UK · GBJohn Radcliffe Hospital · GBUniversity of Ulster · GB

Funding

Medical Research Council G1000467Medical Research Council MR/K006312/1Wellcome Trust
6 · The paper itself

Abstract

Familial hypocalciuric hypercalcemia (FHH) is a genetically heterogeneous disorder with three variants, FHH1 to FHH3. FHH1 is caused by loss-of-function mutations of the calcium-sensing receptor (CaSR), a G-protein coupled receptor that predominantly signals via G-protein subunit alpha-11 (Gα11 ) to regulate calcium homeostasis. FHH2 is the result of loss-of-function mutations in Gα11 , encoded by GNA11, and to date only two FHH2-associated Gα11 missense mutations (Leu135Gln and Ile200del) have been reported. FHH3 is the result of loss-of-function mutations of the adaptor protein-2 σ-subunit (AP2σ), which plays a pivotal role in clathrin-mediated endocytosis. We describe a 65-year-old woman who had hypercalcemia with normal circulating parathyroid hormone concentrations and hypocalciuria, features consistent with FHH, but she did not have CaSR and AP2σ mutations. Mutational analysis of the GNA11 gene was therefore undertaken, using leucocyte DNA, and this identified a novel heterozygous GNA11 mutation (c.161C>T; p.Thr54Met). The effect of the Gα11 variant was assessed by homology modeling of the related Gαq protein and by measuring the CaSR-mediated intracellular calcium (Ca(2+) i ) responses of HEK293 cells, stably expressing CaSR, to alterations in extracellular calcium (Ca(2+) o ) using flow cytometry. Three-dimensional modeling revealed the Thr54Met mutation to be located at the interface between the Gα11 helical and GTPase domains, and to likely impair GDP binding and interdomain interactions. Expression of wild-type and the mutant Gα11 in HEK293 cells stably expressing CaSR demonstrate that the Ca(2+) i responses after stimulation with Ca(2+) o of the mutant Met54 Gα11 led to a rightward shift of the concentration-response curve with a significantly (p < 0.01) increased mean half-maximal concentration (EC50 ) value of 3.88 mM (95% confidence interval [CI] 3.76-4.01 mM), when compared with the wild-type EC50 of 2.94 mM (95% CI 2.81-3.07 mM) consistent with a loss-of-function. Thus, our studies have identified a third Gα11 mutation (Thr54Met) causing FHH2 and reveal a critical role for the Gα11 interdomain interface in CaSR signaling and Ca(2+) o homeostasis. © 2016 American Society for Bone and Mineral Research.

Indexed as

GTP-Binding Protein alpha SubunitsHypercalcemiaMutation, MissenseAgedAmino Acid SubstitutionCalcium SignalingFemaleFibroblast Growth Factor-23HEK293 CellsHumansProtein DomainsReceptors, Calcium-SensingCASR protein, humanFGF23 protein, humanFibroblast Growth Factor-23GNA11 protein, humanGTP-Binding Protein alpha SubunitsReceptors, Calcium-SensingCELL/TISSUE SIGNALING - ENDOCRINE PATHWAYSDISORDERS OF CALCIUM/PHOSPHATE METABOLISMPARATHYROID-RELATED DISORDERSPTH/VIT D/FGF23

Identifiers

PMID26729423
PMCPMC4949650
OpenAlexW2227989665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.